Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia.
Immunovant, Inc. is based in New York, New York.
Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -0.74 Decreased by -64.44% | -0.60 Decreased by -23.33% |
| Aug 6, 24 | -0.60 Decreased by -5.26% | -0.53 Decreased by -13.21% |
| May 29, 24 | -0.52 Decreased by -13.04% | -0.43 Decreased by -20.93% |
| Feb 12, 24 | -0.36 Increased by +26.53% | -0.43 Increased by +16.28% |
| Nov 9, 23 | -0.45 Decreased by -9.76% | -0.47 Increased by +4.26% |
| Aug 10, 23 | -0.57 Decreased by -62.86% | -0.45 Decreased by -26.67% |
| May 22, 23 | -0.46 Decreased by -12.20% | -0.43 Decreased by -6.98% |
| Feb 3, 23 | -0.49 Decreased by -36.11% | -0.39 Decreased by -25.64% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -109.12 M Decreased by -86.01% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -87.15 M Decreased by -17.87% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 1.50 M Increased by +N/A% | -75.32 M Decreased by -26.73% | Decreased by -5.02 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -51.42 M Increased by +18.68% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -58.66 M Decreased by -22.40% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -73.94 M Decreased by -83.13% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -59.43 M Decreased by -25.99% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -63.23 M Decreased by -52.78% | Decreased by N/A% Decreased by N/A% |